BridgeBio posts PROPEL 3 Phase 3 infigratinib data in children with achondroplasia presentation

• BridgeBio published results from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia.
• Primary endpoint met at week 52, with annualized height velocity up 1.74 cm/year versus placebo (95% CI 1.31-2.17; p<0.0001).
• Height z-score improved 0.32 versus placebo at week 52 (96% CI 0.23-0.41; p<0.0001).
• Exploratory measures showed lower apnea-hypopnea index progression, with otitis media event rates down 38% versus placebo.
• Safety profile appeared comparable to placebo, with mostly Grade 1-2 events; no treatment-related serious adverse events or discontinuations reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.